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Dear Editor:
With interest we read the paper ‘A minimum yield of twelve
lymph nodes in rectal cancer remains valid in the era of neo-
adjuvant treatment’ by Lykke et al. published on 5 February
2015 [Epub ahead of print]. In this study, the authors found an
association between increased lymph node yield and the de-
tection of node positive disease up to a lymph node yield of 12
to 17 nodes for rectal cancer patients (irrespective of neo-
adjuvant treatment). They reason that this indicates that a yield
of at least 12 lymph nodes is needed to ensure node negative
disease, and that guidelines on a minimum yield of 12 lymph
nodes are valid.
Althoughwe agree with the authors that an adequate lymph
node evaluation is important for correct staging and subse-
quent treatment of patients, we do not believe that their con-
clusion is justified that the adequacy of lymph node yield and
staging can be determined on the basis of a certain minimum
number of lymph nodes evaluated. In our opinion, certain
important aspects were not taken into account in this study.
In the last two decades, the number of lymph nodes evalu-
ated has become a surrogate marker for surgical and patholog-
ical excellence in colorectal cancer. Quality initiatives aimed
at improving nodal yield have been undertaken and have re-
sulted in an increase in the number of lymph nodes evaluated
over time, indicating that room for improvement in surgical
and pathological practices existed. However, a ceiling may
have been reached beyond which further improvement might
not be possible. This can be explained by the fact that the
number of lymph nodes available for evaluation is not only
influenced by the thoroughness of the surgeon and the dili-
gence of the pathologist but also by a patient’s ability to mount
an effective immune response to the tumour. A growing body
of literature (i.e. studies by Pages and Galon et al. in the New
England Journal of Medicine, Science and Journal of Clinical
Oncology) is showing that the biological behaviour of the
tumour and host, such as immune response, also affects the
number of traceable lymph nodes. A smaller number of lymph
nodes reflects a diminished immune response and is also as-
sociated with less prominent lymphocytic infiltration into the
primary tumour. Consequently, it may be unrealistic to only
define a lymph node evaluation as adequate in case 12 or more
lymph nodes are yielded.
Additionally, other recent studies among colon and rectal
cancer patients such as the study by Parsons et al. in the Jour-
nal of the American Medical Association in 2011 and the
study by Van Erning et al. in European Journal of Cancer in
2014 show that despite increases in lymph node yield over
time, the proportion of lymph node positivity has remained
unchanged, which makes one question the presumed
understaging mechanism.
Therefore, we believe that adequacy of lymph node yield
and staging in rectal cancer should not be determined based on
a minimum number of lymph nodes evaluated. Surgeons and
pathologists should strive to remove and evaluate all lymph
nodes in the resection specimen, while acknowledging that
fewer than 12 lymph nodes might be present in some patients.
The absolute number of lymph nodes evaluated should not be
used as a marker of quality but should rather be regarded as a
reflection of immune response.
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